Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Assets Average (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Assets Average for 4 consecutive years, with $679.5 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 20.28% to $679.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $679.5 million through Dec 2025, up 20.28% year-over-year, with the annual reading at $629.2 million for FY2025, 8.78% up from the prior year.
  • Assets Average hit $679.5 million in Q4 2025 for Axsome Therapeutics, up from $654.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $679.5 million in Q4 2025 to a low of $134.6 million in Q2 2022.
  • Historically, Assets Average has averaged $504.0 million across 4 years, with a median of $565.0 million in 2024.
  • Biggest five-year swings in Assets Average: skyrocketed 271.89% in 2023 and later dropped 8.48% in 2024.
  • Year by year, Assets Average stood at $335.2 million in 2022, then skyrocketed by 77.36% to $594.5 million in 2023, then dropped by 4.97% to $565.0 million in 2024, then grew by 20.28% to $679.5 million in 2025.
  • Business Quant data shows Assets Average for AXSM at $679.5 million in Q4 2025, $654.5 million in Q3 2025, and $618.2 million in Q2 2025.